International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-5 doi: 10.5281/zenodo.12787788
Original Research Article
Efficacy of MRI and CT in Differentiating Benign From Malignant Liver Lesions
Published
Sept. 25, 2024
Abstract

Liver lesions represent a broad spectrum of pathological entities ranging from benign tumors, such as hemangiomas, to malignant ones like hepatocellular carcinoma (HCC). Accurate differentiation between benign and malignant liver lesions is essential for appropriate clinical management. This study aims to compare the diagnostic efficacy of computed tomography (CT) and magnetic resonance imaging (MRI) in distinguishing benign from malignant liver lesions. Conducted over a two-year period at ShriVasantraoNaik Government Medical College Yavatmal, the study involved 50 patients who underwent both CT and MRI, with histopathological confirmation serving as the gold standard. MRI demonstrated higher sensitivity (90%), specificity (85%), and overall accuracy (88%) compared to CT, which exhibited a sensitivity of 80%, specificity of 75%, and accuracy of 78%. MRI's superior soft-tissue contrast and advanced imaging sequences contributed to better lesion characterization, while CT remained valuable for initial detection and emergencies. The findings suggest that MRI is the preferred modality for differentiating liver lesions, particularly when the precise diagnosis is critical for treatment planning.

Recommended Articles
Loading Image...
Volume-5, Issue-5
Citations
141 Views
260 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved